Skip to main content
padlock icon - secure page this page is secure

Safety monitoring of cardiac and hepatic systems in -thalassemia patients with chelating treatment in Taiwan

Buy Article:

$59.00 + tax (Refund Policy)

Peng C-T, Chow K-C, Chen J-H, Chiang Y-P, Lin T-Y, Tsai C-H. Safety monitoring of cardiac and hepatic systems in -thalassemia patients with chelating treatment in Taiwan.

Eur J Haematol 2003: 70: 392–397. © Blackwell Munksgaard 2003. Abstract:

We conducted a prospective 3-yr clinical study comparing deferiprone (L1) with desferrioxamine (DFX). The therapeutic efficacy and potential side-effects on cardiac and/or hepatic systems of thalassemia patients were assessed by left ventricular ejection fraction, T2-weighted magnetic resonance imaging, and biochemical parameters. In both groups, levels of serum ferritin decreased significantly, and the hepatic function improved notably. Besides decrement of iron, no marked pathohistological changes were observed in the liver biopsies. These results indicated that for patients who failed to respond to DFX treatment, the use of L1 to remove excess iron deposition is recommended.
No References
No Citations
No Supplementary Data
No Article Media
No Metrics

Keywords: cardiac; cardiac function; chelation; deferiprone; desferrioxamine; iron overload; left ventricular ejection fraction; magnetic resonance imaging; thalassemia

Document Type: Research Article

Affiliations: 1: Departments of Paediatrics, 2: Medical Research, 3: Radiology and 4: Pathology, China Medical College Hospital and Institute of Medical Sciences, China Medical College, Taichung, Taiwan

Publication date: June 1, 2003

  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content
Cookie Policy
X
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more